The Relative Strength (RS) Rating for Agilon Health (AGL) entered a new percentile Wednesday, with an increase from 77 to 82.
This unique rating tracks market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the last 52 weeks matches up against other publicly traded companies.
Decades of market research shows that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 in the early stages of their moves.
Agilon Health is now considered extended and out of buy range after clearing a 34.23 buy point in a first-stage ipo base. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
The company reported -50% earnings growth in its most recent report. Revenue increased 42%.
The company earns the No. 6 rank among its peers in the Commercial Services-Healthcare industry group. Corvel (CRVL) and Vocera Communications (VCRA) are also among the group's highest-rated stocks.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.